Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Michel Dahan Insider Profile
4 Followers
Michel Dahan, SVP, COO at Akebia Therapeutics, holds 706.93K shares in Akebia Therapeutics (Ticker: AKBA). Most recently, Michel Dahan Sold $8,661 shares of Akebia Therapeutics on Mar 01, 2024 for an estimated value of 13.68K.
Profitable Transactions
8 out of 14 Profitable Transactions
Average Return
-2.60%
Average return per transaction
Time Frame
Compare to
Insider Roles
SVP, COO
Roles that Michel Dahan holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Apr 01, 2021 - Apr 01, 2022
Return:+79.90%
The most profitable trade made by Michel Dahan
Michel Dahan's Trading History
List of latest transactions for each holding click on a transaction to see Michel Dahan's performance on stock
You May Also Like
Michel Dahan insider profile FAQ
What is the percentage of profitable transactions made by Michel Dahan?
The percentage of profitable transactions made by Michel Dahan is 57%.
What is the average return per transaction made by Michel Dahan?
The average return per transaction made by Michel Dahan is -2.60%.
What stocks does Michel Dahan hold?
Michel Dahan holds: AKBA stocks.
What was Michel Dahan’s latest transaction?
Michel Dahan latest transaction was an Informative Sell of $13.68K.
What was Michel Dahan's most profitable transaction?
Michel Dahan’s most profitable transaction was an Informative Sell of AKBA stock on April 1, 2021. The return on the trade was 79.90%.
What is Michel Dahan's role in Akebia Therapeutics?
Michel Dahan's role in Akebia Therapeutics is SVP, COO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.